Usuario:
Evaluación y uso del Modelo
Descripción
Modelo A8 - Quimioterapia: agente citotóxico sistémico
El modelo se evalúa tanto en forma formal como empírica. La evaluación formal determina en qué medida la red lógica se basa en principios físicos o en relaciones matemáticas ajustadas a la realidad pero sin sustento causal, y en qué medida cada variable proviene de un principio general o de un ajuste específico a la operación observada. La evaluación empírica, en paralelo, corre experimentos o compara con datos medidos para validar que el modelo predice correctamente lo que va a ocurrir.
Tras estas validaciones —y con las incertidumbres y resguardos que corresponda mantener— el modelo puede usarse en simuladores que pronostican el comportamiento del sistema según la situación que se está estudiando.
ID:3522
Estructura de los Grupos
Descripción
El primer paso consiste en analizar la descripción general del modelo e identificar los distintos aspectos que intervienen en el fenómeno y que deben ser representados. Cada uno de estos aspectos se organiza como un grupo, entendido como una unidad conceptual coherente que describe una parte específica del funcionamiento del modelo.
Cada grupo reúne los objetos o conceptos relevantes para ese aspecto y las relaciones o verbos que describen cómo interactúan, se modifican o dependen unos de otros. De esta manera, cada grupo constituye una parte de la red semántica del modelo, mientras que el conjunto de los grupos permite representar de forma estructurada su funcionamiento global.
La división en grupos facilita además separar mecanismos, condiciones, procesos y resultados que cumplen funciones diferentes dentro del modelo, manteniendo al mismo tiempo las relaciones que existen entre ellos. Los grupos no son, por tanto, componentes aislados: pueden compartir conceptos y establecer relaciones entre sí, formando conjuntamente una única representación semántica del fenómeno.
La imagen anterior ofrece una visión general de los distintos aspectos en que se ha estructurado el modelo. A continuación se presentan los grupos identificados, indicando para cada uno su título y una breve descripción del aspecto del modelo que representa.
Grupo 1: Grupo 1: Cytotoxic action and proliferation selectivity
Cytotoxic agents interfere with DNA replication or cell division, so damage increases with proliferative activity. Tumor cells are preferentially affected because they generally divide more rapidly, but high-turnover healthy tissues such as bone marrow, mucosa, and hair follicles are damaged by the same selectivity. The relevant qualitative dependency is therefore increasing cytotoxic effect with increasing fraction or rate of actively dividing cells, without a tumor-exclusive threshold.
Grupo 2: Grupo 2: Fractional cell kill and repeated cycles
Each chemotherapy dose removes approximately a fixed fraction of the tumor cells present rather than a fixed number. The surviving burden after one cycle is therefore proportional to the burden before that cycle, and repeated cycles multiply this reduction successively. More cycles decrease the surviving tumor-cell population toward a clinically low level, while each individual cycle leaves a proportional residual population.
Grupo 3: Grupo 3: Growth fraction and treatment scheduling
The fraction killed per cycle depends on the fraction of tumor cells actively dividing. The source states that a large tumor can have a higher active growth fraction than a smaller established residual tumor, making chemotherapy more effective while that fraction is high; this motivates preoperative treatment in the described scenario. Shortening the interval between cycles also reduces the time available for regrowth, so efficacy depends jointly on growth fraction and inter-cycle interval.
Grupo 4: Grupo 4: Bone-marrow suppression and neutrophil recovery
Each cytotoxic cycle suppresses bone-marrow progenitor production, after which circulating neutrophils decline with a delay of roughly one to two weeks to a nadir and then recover over subsequent weeks. Febrile neutropenia occurs when the neutrophil count falls below a critical threshold together with fever. A marrow-stimulating drug accelerates neutrophil production and is described as shortening both the time to nadir and the subsequent recovery period.
Grupo 5: Grupo 5: Mutation, resistance, and combination therapy
Every tumor-cell division carries a small approximately constant probability of acquiring resistance to a particular drug. As total tumor-cell number increases, the probability that at least one resistant cell exists approaches certainty even when the per-cell probability is small. Combining drugs with distinct mechanisms reduces joint resistance because a cell would need resistance to all combined agents simultaneously, making the combined-resistance probability much smaller than single-drug resistance.
Grupo 6: Grupo 6: Therapeutic window and individualized dosing
For cytotoxic chemotherapy the effective dose lies close to the dose that becomes toxic to the organism, creating a narrow therapeutic window. Drug concentration in blood can be measured after administration, and dose can be individualized using body weight, body-surface area, renal function, hepatic function, and measured exposure. The clinical objective is to reduce inter-patient variability while approaching effective exposure without crossing the toxicity boundary.
Grupo 7: Grupo 7: Integrated cycle-by-cycle treatment control
Clinical chemotherapy design adjusts tumor fractional kill, growth fraction, marrow toxicity and recovery, resistance risk, drug combinations, and dosing together across successive cycles. Cycle number and spacing determine cumulative tumor reduction and regrowth opportunity; neutrophil nadir surveillance constrains safe continuation; combination therapy constrains resistance; and individualized dose/exposure constrains toxicity. The resulting regimen is therefore a coupled control problem rather than a single-dose intervention.
ID:1245